Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Business Officer

President and CEO

CFO and Secretary

SVP, Clinical Operations

Senior VP, Clinical Operations

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2023-11-16	Premium	bought	Premium	Premium	Premium	Chief Business Officer
2023-06-23	Premium	bought	Premium	Premium	Premium	-
2023-06-23	Premium	bought	Premium	Premium	Premium	-
2023-06-23	Premium	bought	Premium	Premium	Premium	President and CEO
2023-06-23	Premium	bought	Premium	Premium	Premium	-
2023-06-23	Premium	bought	Premium	Premium	Premium	-
2023-06-23	Premium	gifted	Premium	Premium	Premium	-
2023-06-23	Premium	bought	Premium	Premium	Premium	CFO and Secretary
2023-06-23	Premium	bought	Premium	Premium	Premium	Chief Business Officer
2023-04-10	Premium	bought	Premium	Premium	Premium	Chief Business Officer
2023-01-03	Premium	acquired	Premium	Premium	Premium	-
2023-01-03	Premium	acquired	Premium	Premium	Premium	-
2023-01-03	Premium	acquired	Premium	Premium	Premium	-
2023-01-03	Premium	acquired	Premium	Premium	Premium	-
2022-12-09	Premium	bought	Premium	Premium	Premium	-
2022-12-08	Premium	bought	Premium	Premium	Premium	-
2022-12-07	Premium	bought	Premium	Premium	Premium	-
2022-12-06	Premium	bought	Premium	Premium	Premium	-
2022-12-05	Premium	bought	Premium	Premium	Premium	-
2022-12-02	Premium	sold	Premium	Premium	Premium	-

DMAC - DiaMedica Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for DMAC